You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: clonidine is more effective than placebo for long term smoking cessation, but has side effects

https://doi.org/10.1136/ebm.10.1.19

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;(3):CD000058.

    
 
 Q Is oral or transdermal clonidine more effective than placebo for achieving long term smoking cessation?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Cochrane Tobacco Addiction Group trials register, Medline, and PsycLIT (up to May 2004); and the email newsgroup of the Society for Research on Nicotine and Tobacco for unpublished studies.

    Embedded ImageStudy selection and assessment:

    randomised, placebo controlled trials that compared oral or transdermal clonidine (maximum daily dosage ⩾0.2 mg) with placebo. Methodological quality of individual studies was assessed for randomisation procedure and blinding.

    Embedded ImageOutcomes:

    smoking cessation at ⩾12 weeks (biochemical verification of sustained abstinence assessed ⩾12 wk after the end of treatment).

    MAIN RESULTS

    6 trials (n = 776) met the inclusion criteria. Assessment of blinding and details of the randomisation procedure were not reported in any of the studies. 4 of the 6 trials used biochemical verification of smoking abstinence …

    View Full Text